Search

A product of the Westernized, high-fat diet, non-alcoholic fatty liver disease (NAFLD) has emerged as the leading cause of chronic liver disease, affecting one-fourth of the world's population. NAFLD is a progressive disease arising from a multisystem response to excess lipids in the blood, adipose tissue, and liver. Despite the prevalence of NAFLD and its well-studied bidirectional association with obesity and type 2 diabetes mellitus and obesity, there is a shocking scarcity of available treatments aside from diet and lifestyle changes. Thus, further research on NAFLD and potential therapies is urgently needed. This paper will illustrate the major pathways associated with NAFLD and address the relevance of adipose tissue and insulin resistance to identify targets for potential medications and treatments.

Transcriptomic analyses represent one of the most powerful tools available to researchers for investigating gene expression, a fundamental principle in the central dogma of biology, utilizing next generation sequencing (NGS) technologies. As the technologies for acquiring RNA sequencing data advance, so do the tools used for data analysis. The ability to process and analyze sequencing data from any experimental context is an invaluable skill. This paper endeavors to provide an understanding of the current technologies and methods available for obtaining and analyzing high-quality transcriptomic data, as well as outline a workflow for executing a bulk RNA sequencing experiment within the context of liver studies.

Interventional radiology plays an important and increasing role in cancer treatment. Follow-up is important to be able to assess treatment success and detect locoregional and distant recurrence and recommendations for follow-up are needed. At ECIO 2018, a joint ECIO-ESOI session was organized to establish follow-up recommendations for oncologic intervention in liver, renal, and lung cancer. Treatments included thermal ablation, TACE, and TARE. In total five topics were evaluated: ablation in colorectal liver metastases (CRLM), TARE in CRLM, TACE and TARE in HCC, ablation in renal cancer, and ablation in lung cancer. Evaluated modalities were FDG-PET-CT, CT, MRI, and (contrast-enhanced) ultrasound. Prior to the session, five experts were selected and performed a systematic review and presented statements, which were voted on in a telephone conference prior to the meeting by all panelists. These statements were presented and discussed at the ECIO-ESOI session at ECIO 2018. This paper presents the recommendations that followed from these initiatives. Based on expert opinions and the available evidence, follow-up schedules were proposed for liver cancer, renal cancer, and lung cancer. FDG-PET-CT, CT, and MRI are the recommended modalities, but one should beware of false-positive signs of residual tumor or recurrence due to inflammation early after the intervention. There is a need for prospective preferably multicenter studies to validate new techniques and new response criteria. This paper presents recommendations that can be used in clinical practice to perform the follow-up of patients with liver, lung, and renal cancer who were treated with interventional locoregional therapies.